Ensysce Biosciences (ENSC) said Wednesday it has received a notice of allowance for PF9001, a medication for treating opioid use disorder, from the US Patent and Trademark Office.
Data showed that the medication reduced the potential for cardiotoxicity and could potentially deliver a prolonged and predictable effect on daily dosing, the biotechnology company said.
Shares were over 125% higher in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.